Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 17, Issue 4, 2006, Pages 1181-1191

  Regidor, Deborah L ^a,b   Kopple, Joel D ^a,b,c   Kovesdy, Csaba P ^d   Kilpatrick, Ryan D ^a,b   McAllister, Charles J ^e   Aronovitz, Jason ^e   Greenland, Sander ^b   Kalantar Zadeh, Kamyar ^a,c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Veteran Affairs ^*  (United States)

^e DAVITA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CALCIUM; CREATININE; DEXTRAN; ERYTHROPOIETIN; FERRITIN; FERROUS GLUCONATE; HEMOGLOBIN; IRON; PARATHYROID HORMONE; PHOSPHORUS; SERUM ALBUMIN; SUCROSE; TRANSFERRIN; VITAMIN D;

ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BODY MASS; CASE MIX; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIABETES MELLITUS; ETHNOLOGY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE; SEX RATIO; STATISTICAL ANALYSIS; SURVIVAL; UNITED STATES;

EID: 33645474065     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005090997     Document Type: Article

References (48)

1. Van Wyck DB, Bailie G, Aronoff G: Just the FAQs: Frequently asked questions about iron and anemia in patients with chronic kidney disease. Am J Kidney Dis 39: 426-432, 2002
2. Eckardt KU: Pathophysiology of renal anemia. Clin Nephrol 53: S2-S8, 2000
3. Pendse S, Singh AK: Complications of chronic kidney disease: Anemia, mineral metabolism, and cardiovascular disease. Med Clin North Am 89: 549-561, 2005
4. Strippoli GF, Manno C, Schena FP, Craig JC: Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev: CD003967, 2003
5. Locatelli F, Pisoni RL, Akizawa T, Cruz JM, DeOreo PB, Lameire NH, Held PJ: Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 44: 27-33, 2004
6. Rao M, Pereira BJ: Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int 68: 1432-1438, 2005
7. Triolo G, Canavese C, Di Giulio S: Reasons for producing guidelines on anemia of chronic renal failure: Dialysis outcome quality initiative of the National Kidney Foundation. Int J Artif Organs 21: 751-756, 1998
8. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996
9. Moreno F, Aracil FJ, Perez R, Valderrabano F: Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 27: 548-556, 1996
10. Auer J, Simon G, Stevens J, Griffiths P, Howarth D, Anastassiades E, Gokal R, Oliver D: Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int 12: 40-42, 1992
11. Collins AJ, Ma JZ, Ebben J: Impact of hematocrit on morbidity and mortality. Semin Nephrol 20: 345-349, 2000
12. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42: 761-773, 2003
13. Kausz AT, Solid C, Pereira BJ, Collins AJ, St Peter W: Intractable anemia among hemodialysis patients: A sign of suboptimal management or a marker of disease? Am J Kidney Dis 45: 136-147, 2005
14. National Kidney Foundation I, Kidney-Dialysis Outcome Quality Initiative: K/DOQI Clinical Practice Guidelines: Anemia of chronic kidney disease. Am J Kidney Dis 37[Suppl 1]: S182-S238, 2001
15. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19[Suppl 2]: ii1-ii47, 2004
16. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070-3080, 2005
17. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD: Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: The 58th annual fall conference and scientific sessions. Hypertension 45: 811-817, 2005
18. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn H Jr, Kopple JD, Greenland S: Revisiting mortality predictability of serum albumin in the dialysis population: Time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 20:1880-1889, 2005
19. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, Greenland S: Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 46: 489-500, 2005
20. Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR: Validation of comorbid conditions on the end-stage renal disease medical evidence report: The CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 11: 520-529, 2000
21. Gunnell J, Yeun JY, Depner TA, Kaysen GA: Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33: 63-72, 1999
22. Tong EM, Nissenson AR: Erythropoietin and anemia. Semin Nephrol 21: 190-203, 2001
23. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 300: 573-578, 1990
24. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180-2189, 2005
25. Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, Lorenzo V, Arieff AI, Luno J: Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int 68: 788-795, 2005
26. Collins AJ: Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int Suppl 80: 44-48, 2002
27. Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity: The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 13: 1642-1644, 1998
28. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin d and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005
29. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
30. McMahon LP, Dawborn JK: Subjective quality-of-life assessment in hemodialysis-patients at different levels of hemoglobin following use of recombinant-human-erythropoietin. Am J Nephrol 12: 162-169, 1992
31. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15: 1425-1430, 2000
32. Rothman K, Greenland S: Sources of bias. In: Modern Epidemiology, edited by Rothman K, Greenland S, Philadelphia, Lippincott-Raven, 1998
33. Drucke TB, Eckardt KU: Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 17[Suppl 5]: 28-31, 2002
34. Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J: Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol 57: 1086-1095, 2004
35. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: 866-876, 2004
36. Barany P, Divino Filho JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29: 565-568, 1997
37. Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreno V, Caramelo C: Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 54: 1337-1343, 1998
38. Sitter T, Bergner A, Schiffl H: Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 15: 1207-1211, 2000
39. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC: Pentoxifylline improves hemoglobin levels in patients with erythropoietin- resistant anemia in renal failure. J Am Soc Nephrol 15: 1877-1882, 2004
40. Del Vecchio L, Pozzoni P, Andrulli S, Locatelli F: Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 15: 137-141, 2005
41. Lopez-Gomez JM, Perez-Flores I, Jofre R, Carretero D, Rodriguez-Benitez P, Villaverde M, Perez-Garcia R, Nassar GM, Niembro E, Ayus JC: Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 15: 2494-2501, 2004
42. Macdougall IC: Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients? Nephrol Dial Transplant 19[Suppl 5]: V73-V78, 2004
43. Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA: Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 92: 153-160, 1999
44. Stenvinkel P: The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 16[Suppl 7]: 36-40, 2001
45. Stenvinkel P, Barany P: Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 17[Suppl 5]: 32-37, 2002
46. Fink J, Blahut S, Reddy M, Light P: Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37: 348-355, 2001
47. Ayus JC, Sheikh-Hamad D: Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 9: 1314-1317, 1998
48. Nassar GM, Fishbane S, Ayus JC: Occult infection of old nonfunctioning arteriovenous grafts: A novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int Suppl 80: 49-54, 2002